News

The National Multiple Sclerosis Society is funding a new survey to understand how people living with multiple sclerosis (MS) weigh risks against benefits when choosing MS therapies. The survey was developed by Dr. Robert Fox, a neurologist, working with colleagues at the Cleveland Clinic and the MS patient…

A case report of a woman with relapsing-remitting multiple sclerosis (RRMS) who developed shingles while being treated with dimethyl fumarate (Tecfidera) has raised questions of whether the drug reactivates the varicella-zoster virus. The study, “Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate,“ was published in…

The Colorado Neurological Institute (CNI), a non-profit research and neurological care organization, will host the “Spotlight on Hope” gala and fundraising event on April 15, celebrating CNI patients, community leaders and physicians. The inaugural event, which combines the group’s Hope Awards and Gala, is part of CNI’s outreach efforts to advance public understanding of brain cancer, attacks like…

Researchers reported that patients with myelitis who later develop multiple sclerosis (MS) might be distinguished from others with myelitis by a number of characteristics, like the location and size of spinal cord lesions, a finding that might help clinicians diagnose MS and initiate treatment at an early stage. Myelitis, an…

PJSC Pharmsynthez, a pharmaceutical company based in Russia, recently announced completed follow-up findings and data analysis from a Phase 2a proof-of-concept clinical trial of its novel therapeutic vaccine Xemys for the treatment of multiple sclerosis (MS). Xemys utilizes Xenetic Biosciences patented ImuXen technology. In the open-label, dose-escalating trial, 20 patients…

The immune system-suppressing multiple sclerosis (MS) drug fingolimod (Gilenya) also has potentially beneficial effects on the nervous system, according to a recent study, “The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration.“  The article appeared online March 12 in an early version of the journal …

Scientists at the Pediatric MS Center at NYU Langone, New York, reported that U.S. adolescents with multiple sclerosis (MS) receiving interferon-beta 1a therapy had a higher body mass index (BMI), more relapses, and were managed differently compared to patients of similar age in seven other countries. The study, “Subcutaneous…

RedHill Biopharma, Ltd. recently announced promising interim results from its ongoing CEASE-MS Phase 2a clinical trial evaluating the safety and efficacy of a fixed dose of RHB-104 as an add-on therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). RHB-104 consists of an oral capsule formulation of an antibiotic combination therapy —…

Researchers at the University of Texas Health Science Center at Houston, in collaboration with various institutions from north America and Europe, found that teriflunomide (Aubagio) is well-tolerated and efficient for long-term treatment of multiple sclerosis (MS). The findings, entitled “Long-term safety and efficacy of teriflunomide,” were…

Editor’s note: The term B-cells is, in fact, a collective term for a group of cells having rather different properties. Some B-cells cells play a role in fighting invading pathogens or flawed cells, and can be wrongfully activated to target normal cells in autoimmune diseases. Regulatory B-cells (Bregs), instead act…

New research from Argentina explores the idea that controlling symptoms of type 2 diabetes (metabolic syndrome) can also beneficially impact multiple sclerosis (MS) disease progression. The study,“Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis,“ appeared March 7 in the journal…

Neuregulin-1 is a signaling molecule of interest in the context of synaptic plasticity ­— the ability of our nerve cells to form new connections and get rid of those that are no longer needed. Now, a study showed that the factor is also indispensable for repairing myelin in models of spinal…

Researchers, working with an animal model of multiple sclerosis (MS), discovered that oral treatment with a synthesized plant peptide, known as cyclotide, halted the progression of clinical symptoms without side effects. The finding offers new hope for the development of an easily available and orally deliverable treatment that might slow or even…

Several clinical trials have shown that alemtuzumab (Lemtrada) effectively reduces relapse rates in patients with multiple sclerosis (MS), and improves disability in the early stages of the disease. A new study adds to evidence of the drug’s efficiency by finding that it affects different aspects of disability to varying degrees, a finding…

The National Multiple Sclerosis Society is welcoming Novartis Pharmaceuticals, for a fifth consecutive year, as a leading national sponsor of Walk MS, its annual fundraising and awareness-raising event. This year’s walks will also again feature the musician and multiple sclerosis (MS) ambassador David Osmond leading the society’s as part…

Natalizumab (Tysabri) harnesses multiple sclerosis (MS) activity by targeting CD49, a molecule on the surface of immune cells. Now, researchers found that the drug reduces the factor on regulatory T-cells to a greater extent than on inflammatory T-cells — a mechanism that might explain disease exacerbation during treatment. The molecule under…

A survey, summarizing the views of 2,600 multiple sclerosis (MS) patients, showed how people manage their disease in real life — and the results offer some surprising insights that might provide clues for future treatment development and optimization. Conducted by a Stanford University-trained geneticist, Dr. Yael Wilnai, results from the…

Damage to the cerebellum in people with multiple sclerosis (MS) is due more to the death of actual nerve cells than the destruction of white matter connections, a new study out of Italy suggests. The article, which challenges previous ideas about how brain damage in MS occurs, is titled “MRI-detectable cortical lesions in the…

Research on a specific type of stem cell found in the placenta, known as decidua-derived mesenchymal stem cells (DMSC), suggests these cells might be the source of future treatments for multiple sclerosis. The report, “Restrained Th17 response and myeloid cell infiltration into the central nervous system by human decidua-derived mesenchymal stem…

Rosacea is an inflammatory skin condition affecting mostly fair-skinned individuals. A study from the University of Copenhagen, Denmark, recently showed that the condition in women is also associated with multiple sclerosis (MS). Recent genome wide association studies (GWAS) have pinpointed genetic risk factors of the disease that also increase…

MediciNova, Inc., announced that MN-166 (ibudilast) has been approved for “fast track” development by the U.S. Food and Drug Administration (FDA) as a potential treatment for progressive multiple sclerosis (MS). Progressive MS includes both the primary progressive (PPMS) and secondary progressive (SPMS) forms of the disease. MediciNova’s MN-166 was licensed from Kyorin Pharmaceuticals for its potential…

Scientists in recent years have wondered whether a link exists between high lactate levels resulting from mitochondrial dysfunction and multiple sclerosis (MS) progression. Now researchers in Italy showed that lactate, a metabolic byproduct, is indeed increased in the cerebrospinal fluid of MS patients and may be a disease driver. Mitochondria are the body’s energy factories,…

According to new research published in the Multiple Sclerosis Journal, environmental factors appear to play a much greater role in the onset of multiple sclerosis (MS) than previously recognized. The study, “Ethnicity and prevalence of multiple sclerosis in east London,” was led by scientists at…

The United Spinal Association, a nonprofit focused on improving the quality of life of people with spinal cord injuries and disorders (SCI/D), a group of conditions that include multiple sclerosis (MS), is collaborating with MedStar National Rehabilitation Hospital and Children’s National Medical Center to study the potential benefits of the bacteria…

Multiple sclerosis was a main focus at the four-day 10th World Congress on Controversies in Neurology (CONy), in Lisbon, Portugal, that concluded on March 20. Among the topics of debate was demyelination as the disease’s main pathogenic precursor and the clinical potential of remyelination. The debate, titled “Can we expect long-term…

Clinical trials have shown that ocrelizumab — an antibody targeting B-cells — is effective in multiple sclerosis (MS). As a result, some researchers and clinicians claim that B-cell depletion is a sufficient therapy in MS, and that drugs targeting other immune cells are obsolete. Not everyone agrees. A debate at…

A major dilemma facing clinicians is whether to continue treatment with disease-modifying drugs, effective in relapsing-remitting multiple sclerosis (RRMS), as the disease progresses to secondary progressive MS (SPMS). In SPMS,  these treatments seem to lose their benefits and — as they are often associated with severe side effects and high costs — clinicians…

Sanofi Genzyme, one of the companies participating in the four-day 10th World Congress on Controversies in Neurology (CONy) in Lisbon, Portugal, that concluded on March 20, 2016, supported several symposiums focused on multiple sclerosis (MS) — including one on B-cell and T-cell therapies. For over a decade, Sanofi Genzyme has worked to develop effective therapies…

Certain therapies used to treat multiple sclerosis (MS) have been associated with opportunistic infections of the central nervous system, including progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain disorder caused by the John Cunningham (JC) virus. The question of whether the risk for opportunistic infections to MS patients outweighs…

Vitamin D is crucial for our general health and it is known that it modulates immune responses. While large studies have shown that supplemental vitamin D lowers the risk of multiple sclerosis (MS), not everyone is convinced. In a debate at the 10th World Congress on Controversies in Neurology (CONy) March…